Multiplexed device for rapid coagulopathy testing

用于快速凝血病检测的多重装置

• 批准号: 10285382
• 负责人: Charles Corey Hardin
• 金额: $ 46.2万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-15 至 2023-09-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10285382
• 关键词: Address; Adult Respiratory Distress Syndrome; Aerosols; Antithrombins; Autopsy; Biological Assay; Biomimetics; Blood; Blood Chemical Analysis; Blood Coagulation Disorders; Blood Coagulation Factor; Blood Platelets; Blood Tests; Blood Vessels; Blood coagulation; Blood coagulation tests; Blood flow; Blood specimen; COVID-19; COVID-19 patient; COVID-19 testing; Case Study; Cessation of life; Characteristics; China; Clinic; Clinical; Clinical assessments; Coagulation Process; Collagen; Complement; Critical Illness; Data; Deposition; Device Designs; Devices; Diagnosis; Dimensions; Disseminated Intravascular Coagulation; Drops; Elements; Etiology; Event; Exhibits; Exposure to; Fibrin; Fibrin fragment D; Fibrinogen; Gel; Geometry; Hemorrhage; Hemostatic function; Hour; Incidence; Inflammation; International Normalized Ratio; Ischemic Bowel Disease; Italy; Life; Lung; Measurement; Measures; Medical; Methods; Microfluidic Microchips; Molds; Myocardial Infarction; Pathway interactions; Patient Care; Patients; Performance; Phenotype; Procedures; Process; Prothrombin time assay; Province; Pulmonary Embolism; Reporting; Resistance; Respiration Disorders; Respiratory Failure; Risk; Role; Sepsis; Stroke; Structure of parenchyma of lung; Surface; Survivors; System; Technology; Testing; Thinness; Thrombelastography; Thrombophilia; Thromboplastin; Thrombosis; Time; Trauma; Travel; Vacuum; Viscosity; Whole Blood; clinical application; clinical practice; cytokine; design; epidemiologic data; experience; experimental study; global health; improved; in vivo; limb ischemia; microfluidic technology; mortality; new technology; point of care testing; pressure; rapid diagnosis; risk minimization; thrombotic; thrombotic complications; tool; venous thromboembolism; ventilation; web site

Abstract COVID-19 has emerged as a global health challenge, with more than 37 million cases reported and 1,079,029 deaths (as of October 13, 2020 according to the WHO website). Although the precise etiology of coagulopathies in COVID-19 is not clear, damage to lung tissue, increased cytokine levels and alteration of blood chemistry due to inflammation and sepsis all likely contribute. The resulting inappropriate hemostasis (the process of making blood clots to stop bleeding) is a major challenge in the care of these patients. Importantly, the coagulation profile of a COVID-19 patient – and consequently the appropriate medical treatment – might change from hour to hour. Because asymptomatic patients can develop life-threatening coagulopathy-related thrombotic events, robust, frequent and inexpensive tests for blood coagulation aberrations would help identify at-risk patients. Current methods for clinical assessment of coagulation status are cumbersome, expensive and limited in scope, and clinicians are frustrated by the lack of robust tools to address coagulopathy in COVID-19. Leveraging our expertise in blood coagulopathy, COVID-19 management and microfluidics technology, we propose to develop and test technology for improving diagnosis of blood coagulation status in COVID-19-positive patients. The technology is simple, but multiplexed, replacing multiple blood tests currently used in the clinic. Because the blood sample is always contained within the device, risk of exposure to infected blood is minimized. It uses biomimetic principles to challenge blood to flow through vascular-like channels that are pre-treated with specific coagulation factors. We will optimize the design of the device and validate its performance against existing assay methods. When complete, this project will provide new technology for rapid, repeated point of care testing of blood coagulopathy in COVID-19 and other diverse clinical applications.

抽象的 COVID-19 已成为一项全球健康挑战，已报告病例数超过 3,700 万例，确诊病例数达 1,079,029 例 死亡人数（截至 2020 年 10 月 13 日，根据世界卫生组织网站）。 在 COVID-19 中尚不清楚，肺组织受损、细胞因子水平增加和血液化学变化是由于 炎症和败血症都可能导致不适当的止血（制造过程）。 血栓止血）是护理这些患者的主要挑战，重要的是凝血。 COVID-19 患者的个人资料以及相应的医疗治疗可能会随时发生变化 因为无症状患者可能会发生危及生命的凝血病相关血栓事件， 对凝血异常进行稳健、频繁且廉价的测试将有助于识别高危患者。 目前临床评估凝血状态的方法繁琐、昂贵且范围有限， 敌人因缺乏强有力的工具来解决 COVID-19 中的凝血障碍而感到沮丧。 我们建议开发凝血病、COVID-19 管理和微流体技术方面的专业知识 以及用于改善 COVID-19 阳性患者凝血状态诊断的测试技术。 技术简单，但多重，取代了目前临床上使用的多种血液测试。 血液样本始终包含在设备内，因此可以最大程度地降低接触受感染血液的风险。 仿生原理挑战血液流经经过特定处理的血管样通道 我们将优化设备的设计并根据现有检测验证其性能。 完成后，该项目将为快速、重复的护理点测试提供新技术。 COVID-19 中的凝血病和其他不同的临床应用。

项目成果

Planning for the Next Pandemic: Trauma Injuries Require Pre-COVID-19 Levels of High-Intensity Resources.

规划下一次大流行：创伤需要 COVID-19 之前水平的高强度资源。

• 发表时间: 2022-06
• 作者: Mokhtari, Ava K;Maurer, Lydia R;Wong, Yee M;Hardman, Claire;Hafiz, Shabnam;Sharrah, Mark;Soe;Peralta, Rafael;Parks, Jonathan J;Rattan, Rishi;Butler, Caroline;Hwabejire, John O;Fawley, Jason;Fagenholz, Peter J;King, David R;Kaafara
• 通讯作者: Kaafara

Adding to the story, did penetrating trauma really increase? changes in trauma patterns during the COVID-19 pandemic: A multi-institutional, multi-region investigation.

加上这个故事，穿透伤真的增加了吗？

• 发表时间: 2022-06
• 影响因子: 2.5
• 作者: Mokhtari, Ava K;Maurer, Lydia R;Dezube, Michael;Langeveld, Kimberly;Wong, Yee M;Hardman, Claire;Hafiz, Shabnam;Sharrah, Mark;Soe;Chapple, Kristina M;Peralta, Rafael;Rattan, Rishi;Butler, Caroline;Parks, Jonathan J;Mendoza, April E
• 通讯作者: Mendoza, April E

Strategies to minimize heterogeneity and optimize clinical trials in Acute Respiratory Distress Syndrome (ARDS): Insights from mathematical modelling.

最小化异质性并优化急性呼吸窘迫综合征 (ARDS) 临床试验的策略：数学模型的见解。

• 发表时间: 2022-01
• 影响因子: 11.1
• 作者: Subudhi, Sonu;Voutouri, Chrysovalantis;Hardin, C Corey;Nikmaneshi, Mohammad Reza;Patel, Ankit B;Verma, Ashish;Khandekar, Melin J;Dutta, Sayon;Stylianopoulos, Triantafyllos;Jain, Rakesh K;Munn, Lance L
• 通讯作者: Munn, Lance L